These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12756164)

  • 1. Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
    Rumpel M; Friedrich T; Deininger MW
    Blood; 2003 Jun; 101(11):4641-3. PubMed ID: 12756164
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
    Kvasnicka HM; Thiele J; Staib P; Schmitt-Graeff A; Griesshammer M; Klose J; Engels K; Kriener S
    Blood; 2004 May; 103(9):3549-51. PubMed ID: 14726401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
    Zipin D; Savage DG
    Leuk Lymphoma; 2004 Nov; 45(11):2363-4. PubMed ID: 15512833
    [No Abstract]   [Full Text] [Related]  

  • 6. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
    Smith CC; Shah NP
    Clin Cancer Res; 2011 Nov; 17(21):6605-7. PubMed ID: 21948230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
    Goldman J
    Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia.
    Piccin A; Conneally E; Lynch M; McMenamin ME; Langabeer S; McCann S
    Leuk Lymphoma; 2006 Jul; 47(7):1394-6. PubMed ID: 16923575
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA
    J Natl Cancer Inst; 1999 Jan; 91(2):102-3. PubMed ID: 9923844
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA licences imatinib mesylate for CML.
    Habeck M
    Lancet Oncol; 2002 Jan; 3(1):6. PubMed ID: 11905608
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
    Giles FJ; Cortes JE; Kantarjian HM
    Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.
    Giannoudis A; Davies A; Harris RJ; Lucas CM; Pirmohamed M; Clark RE
    Leukemia; 2014 Jun; 28(6):1360-3. PubMed ID: 24441286
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
    Park J; Kim S; Oh JK; Kim JY; Yoon SS; Lee D; Kim Y
    J Biochem Mol Biol; 2005 Nov; 38(6):725-38. PubMed ID: 16336789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
    Jin L; Tabe Y; Konoplev S; Xu Y; Leysath CE; Lu H; Kimura S; Ohsaka A; Rios MB; Calvert L; Kantarjian H; Andreeff M; Konopleva M
    Mol Cancer Ther; 2008 Jan; 7(1):48-58. PubMed ID: 18202009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
    Einwallner E; Jaeger E; Mitterbauer-Hohendanner G; Bilban M; Simonitsch-Klupp I; Steiner I; Pernicka E; Hoermann G; Herndlhofer S; Sillaber C; Valent P; Schwarzinger I
    Stem Cells Dev; 2013 Dec; 22(23):3043-51. PubMed ID: 23883175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.